The Role of CCL28 in HIV Immunity
Author Information
Author(s): Castelletti Eleonora, Lo Caputo Sergio, Kuhn Louise, Borelli Manuela, Gajardo Johanna, Sinkala Moses, Trabattoni Daria, Kankasa Chipepo, Lauri Eleonora, Clivio Alberto, Piacentini Luca, Bray Dorothy H., Aldrovandi Grace M., Thea Donald M., Veas Francisco, Nebuloni Manuela, Mazzotta Francesco, Clerici Mario
Primary Institution: University of Milano
Hypothesis
Does CCL28 modulate mucosal immunity in HIV infection and exposure?
Conclusion
CCL28 mediates mucosal immunity in HIV exposure and infection, suggesting its potential use in mucosal vaccines.
Supporting Evidence
- CCL28 concentrations were significantly higher in breast milk from HIV-infected women with HIV-specific IgA.
- Higher CCL28 levels in breast milk were associated with better survival rates in HIV-infected children.
- CCL28 was found to be increased in the plasma and saliva of HIV-exposed individuals compared to healthy controls.
Takeaway
CCL28 is a special protein that helps the body fight HIV by attracting important immune cells to the right places.
Methodology
Breast milk samples were collected from HIV-infected women, and CCL28 levels were measured and compared with controls.
Potential Biases
Potential bias in participant selection and self-reported sexual history.
Limitations
The study's sample size for uninfected controls was small, which may affect the significance of some results.
Participant Demographics
Participants included 65 HIV-infected women and 9 uninfected Zambian women, with additional samples from HIV-exposed partners.
Statistical Information
P-Value
0.012
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website